TP53 and neoplasm: With the massive effort of genomic studies and precision oncology approaches [15–20], it is well understood that millions of patients worldwide live with a p53 mutant expressing tumour, with subsequent potential defects in cell death [21–24] or autophagy [25–29], however this information does not currently reflect a benefit for patients as effective therapeutic approaches to target p53 gain-of-function (GOF) are still lacking.